The Food and Drug Administration requested that AcelRx Pharmaceuticals Inc. (Nasdaq: ACRX)
conduct an additional clinical study for its pain medication Zalviso sending the stock price plummeting $3.23 to close at $5.51.
AcelRx must conduct additional study
March 09, 2015 at 16:59 PM EDT
